Moneycontrol PRO
Open App
Live Now | Traders Conclave 2022 | India's Largest Retail Stock Investors & Traders Residential Conclave
you are here: HomeNewsTrendsHealth

Antibodies that can block Omicron variant identified

The research, published in the journal Nature, may help design vaccines and antibody treatments that will be effective against not only Omicron but other variants that may emerge in the future.

December 29, 2021 / 12:47 PM IST
Representative image: Reuters

Representative image: Reuters

Scientists have identified antibodies that neutralise Omicron and other variants of coronavirus by targeting areas that remain essentially unchanged as the virus mutates.

The research, published in the journal Nature, may help design vaccines and antibody treatments that will be effective against not only Omicron but other variants that may emerge in the future.

"This finding tells us that by focusing on antibodies that target these highly conserved sites on the spike protein, there is a way to overcome the virus’ continual evolution,” said David Veesler, an associate professor at the University of Washington School of Medicine in the US.

The Omicron variant has an unusually high number of 37 mutations in the spike protein, which the virus uses to enter and infect the human cells.

It is thought that these changes explain in part why the variant has been able to spread so rapidly, to infect people who have been vaccinated and to reinfect those who have previously been infected.

Close

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

"The main questions we were trying to answer were: how has this constellation of mutations in the spike protein of the Omicron variant affected its ability to bind to cells and to evade the immune system’s antibody responses,” Veesler said.

To assess the effect of these mutations, the researchers engineered a disabled, nonreplicating virus, called a pseudovirus, to produce spike proteins on its surface, as coronaviruses do.

They then created pseudoviruses that had spike proteins with the Omicron mutations and those found on the earliest variants identified in the pandemic.

The researchers first looked to see how well the different versions of the spike protein were able to bind to protein on the surface of cells, that the virus uses to latch onto and enter the cell.

This protein is called the angiotensin converting enzyme-2 (ACE2) receptor.

They found the Omicron variant spike protein was able to bind 2.4 times better than spike protein found in the virus isolated at the very beginning of the pandemic.

"That is not a huge increase but in the SARS outbreak in 2002-2003, mutations in the spike protein that increased affinity were associated with higher transmissibility and infectivity,” Veesler noted.

They also found that the Omicron version was able to bind to mouse ACE2 receptors efficiently, suggesting Omicron might be able to "ping-pong" between humans and other mammals.

The researchers then looked at how well antibodies against earlier isolates of the virus protected against the Omicron variant.

They did this by using antibodies from patients who had previously been infected with earlier versions of the virus, vaccinated against earlier strains of the virus, or had been infected and then vaccinated.

The team found that antibodies from people who had been infected by earlier strains and from those who had received one of the six most-used vaccines currently available all had reduced ability to block infection.

Antibodies from people who had been infected, recovered, and then had two doses of vaccine also had reduced activity, but the reduction was less, about fivefold, clearly demonstrating that vaccination after infection is useful.

Antibodies from people, in this case a group of renal dialysis patients, who had received a booster with a third dose of the mRNA vaccines produced by Moderna and Pfizer showed only a 4-fold reduction in neutralising activity.

"This shows that a third dose is really, really helpful against Omicron,” Veesler said.

All but one antibody treatments currently authorised or approved to be used with patients exposed to the virus, had no or had markedly reduced activity against Omicron in the laboratory.

The exception was an antibody called sotrovimab, which had a two- to three-fold reduction of neutralising activity, the researchers said.

However, when they tested a larger panel of antibodies that have been generated against earlier versions of the virus, the researchers identified four classes of antibodies that retained their ability to neutralise Omicron.

Members of each of these classes target one of four specific areas of the spike protein present in not only SARS-CoV-2 variants but also a group of related coronaviruses, called sarbecoviruses.

These sites on the protein may persist because they play an essential function that the protein would lose if they mutated. Such areas are called "conserved.”

The finding that antibodies are able to neutralise via recognition of conserved areas in so many different variants of the virus suggests that designing vaccines and antibody treatments that target these regions could be effective against a broad spectrum of variants, Veesler added.
PTI
first published: Dec 29, 2021 12:47 pm
Sections
ISO 27001 - BSI Assurance Mark